Cerebrospinal Fluid (CSF) Raltegravir Substudy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00718029|
Recruitment Status : Unknown
Verified July 2008 by University of California, San Diego.
Recruitment status was: Enrolling by invitation
First Posted : July 18, 2008
Last Update Posted : July 24, 2008
The purpose of this study is to measure concentrations of Raltegravir in cerebrospinal fluid.
The hypotheses are:
- Raltegravir concentrations in CSF will be measurable
- Raltegravir concentrations in CSF will remain constant, while plasma concentrations vary widely leading to highly variable CSF-to-plasma ratios.
- Following at least 4 weeks of Raltegravir-containing combination therapy, HIV RNA levels in CSF will be below 50 copies/mL in all subjects.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||MK: Raltegravir Concentrations in Cerebrospinal Fluid|
|Study Start Date :||July 2008|
|Estimated Primary Completion Date :||July 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00718029
|Principal Investigator:||Scott L Letendre, MD||University of California, San Diego AntiViral Research Center|